Immune Response to Influenza Vaccine in Adults With B-cell Malignancies

Updated 04/16/2024

Status Terminated

Clinical Trial Summary

The primary objective of this study is to assess the immune response to an influenza vaccine in adults with B-cell malignancies who are currently receiving treatment with idelalisib in a Gilead-sponsored study (parent study).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03701438
Study type	Observational
Source	Gilead Sciences
Contact
Status	Terminated
Phase
Start date	October 23, 2018
Completion date	October 9, 2019

See also
	Status	Clinical Trial	Phase
	Completed	`NCT02343120` - Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies	Phase 1/Phase 2
	Completed	`NCT02018861` - A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)	Phase 1/Phase 2
	Completed	`NCT02327078` - A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)	Phase 1/Phase 2
	Completed	`NCT04551963` - Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies	Phase 1
	Recruiting	`NCT05683717` - A Phase 1 Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies	Phase 1
	Completed	`NCT01775631` - Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma	Phase 1
	Active, not recruiting	`NCT01905813` - Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies	Phase 1
	Recruiting	`NCT05275504` - Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies	Phase 1
	Active, not recruiting	`NCT02457598` - Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies	Phase 1
	Recruiting	`NCT03050190` - A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Malignancies	Phase 1/Phase 2
	Recruiting	`NCT03125577` - Combination CAR-T Cell Therapy Targeting Hematological Malignancies	Phase 1/Phase 2
	Enrolling by invitation	`NCT04170283` - Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Participants With B-cell Malignancies	Phase 3
	Recruiting	`NCT04509700` - Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)	Phase 2
	Not yet recruiting	`NCT03642496` - Clinical Study of ET019002-T Cell Therapy for Refractory/Relapsed B-Cell Malignancies	Early Phase 1
	Completed	`NCT00983619` - A Clinical Study Using MEDI-551 in Adult Participants With Relapsed or Refractory Advanced B-Cell Malignancies	Phase 1/Phase 2